A Phase 3 interventional study of Varenicline and Positively Smoke Free in Smoking and HIV, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by University of Maryland, Baltimore · Phase 3, Interventional, and Treatment
The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.
The study used a factorial design to randomize participants into 4 conditions: (1) Varenicline (12 weeks) + Positively Smoke Free (PSF) (8 weeks); (2) Varenicline (12 weeks) + Standard of Care (brief advice to quit); (3) Placebo (12 weeks) + Positively Smoke Free (8 weeks); and (4) Placebo (12 weeks) + Standard of Care. The primary outcome was the 7-day point prevalence abstinence (PPA) (\<10mm) at 36 weeks.
The specific aims of our proposal are:
Primary Aim 1: Compare varenicline to placebo on rates of 7-day point prevalence abstinence (PPA) at 36 weeks in smokers with HIV/AIDS. We hypothesize that rates of smoking abstinence at week 36 will be higher in those treated with varenicline compared to placebo.
Primary Aim 2: Compare Positively Smoke Free to low intensity, brief counseling on rates of 7-day PPA at 36 weeks in smokers with HIV/AIDS. We hypothesize that rates of smoking abstinence at week 36 will be higher in those treated with Positively Smoke Free compared to brief counseling.
Primary Aim 3: Compare Positively Smoke Free + varenicline to the other two study conditions outlined above on rates of 7-day PPA in smokers with HIV/AIDS at 36 weeks. We hypothesize the effect of PSF with varenicline is greater than the effect of PSF or varenicline alone.
Exporatory Aim: Explore the effect of successful cessation/smoking abstinence on levels of cardiac specific biomarkers, nicotine biomarkers, generalized markers of inflammation, lipids, coagulation and monocyte/macrophage activation.
2,040 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 272 are open to participants now.
This study's enrollment of 184 is above the median of 105 across 1,543 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →University of Maryland, Baltimore is the lead sponsor of 687 studies on the registry; 130 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 63 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Study Inclusion Criteria:
Study Exclusion Criteria:
The exclusion criteria are designed to maximize safety by minimizing drug interactions or worsening pre-existing comorbid psychiatric or medical conditions:
Participants will receive varenicline and standard of care
Drug: Varenicline · Behavioral: Standard of Care
Participants will receive placebo and standard of care
Drug: Placebo · Behavioral: Standard of Care
Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
Behavioral: Positively Smoke Free · Drug: Placebo
Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
Drug: Varenicline · Behavioral: Positively Smoke Free
Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks
7-day point-prevalence abstinence based onno self-reported tobacco use (not even a puff) during the 7 days preceding the assessment and a CO ≤10ppm as measured by Covita micro smokrlyzer at week 36.
Time frame: 36 weeks
Biomarker Evaluation
Effect of smoking abstinence on levels of cardiac specific biomarkers
Time frame: 36 weeks
| Milestone | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline |
|---|---|---|---|---|
| Started | 46 | 47 | 42 | 49 |
| Completed | 36 | 37 | 28 | 30 |
| Not completed | 10 | 10 | 14 | 19 |
7-day point-prevalence abstinence based onno self-reported tobacco use (not even a puff) during the 7 days preceding the assessment and a CO ≤10ppm as measured by Covita micro smokrlyzer at week 36.
| Participants | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline |
|---|---|---|---|---|
| Number of Participants With 7-day Point Prevalence Abstinence at 36 Weeks | 5 | 4 | 1 | 5 |
Effect of smoking abstinence on levels of cardiac specific biomarkers
Results for this outcome have not been posted.
Collected over 12 weeks--This is the timeframe for the medication related non-serious adverse events as the medication part of the trial was discontinued after 12 weeks. 36 weeks--This is the timeframe for all cause mortality and serious adverse events. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline + Standard of Care | 0/46 (0%) | 0/46 (0%) | 33/46 (71.7%) |
| Placebo + Standard of Care | 0/47 (0%) | 0/47 (0%) | 30/47 (63.8%) |
| Positively Smoke Free + Placebo | 0/42 (0%) | 0/42 (0%) | 25/42 (59.5%) |
| Positively Smoke Free + Varenicline | 0/49 (0%) | 0/49 (0%) | 32/49 (65.3%) |
| Event | Varenicline + Standard of Care | Placebo + Standard of Care | Positively Smoke Free + Placebo | Positively Smoke Free + Varenicline |
|---|---|---|---|---|
| Increased appetiteGastrointestinal disorders | 7/46 | 7/47 | 13/42 | 4/49 |
| Dry mouthGastrointestinal disorders | 13/46 | 6/47 | 4/42 | 3/49 |
| NauseaGastrointestinal disorders | 9/46 | 6/47 | 4/42 | 8/49 |
| stiffnessMusculoskeletal and connective tissue disorders | 2/46 | 1/47 | 7/42 | 1/49 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 6/46 | 3/47 | 3/42 | 8/49 |
| Abnormal dreamsPsychiatric disorders | 6/46 | 6/47 | 3/42 | 2/49 |
| DizzinessNervous system disorders | 3/46 | 6/47 | 1/42 | 6/49 |
| HeadacheNervous system disorders | 4/46 | 6/47 | 5/42 | 4/49 |
| GERDGastrointestinal disorders | 5/46 | 3/47 | 2/42 | 4/49 |
| Abdominal painGastrointestinal disorders | 5/46 | 0/47 | 3/42 | 2/49 |
| Age, Continuous(years) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Mean | 51.5 ± 10.7 | 52.0 ± 8.5 | 55.3 ± 8.1 | 52.6 ± 10.3 | 52.8 ± 9.6 |
| Sex/Gender, Customized(participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Male | 32 | 30 | 25 | 28 | 115 |
| Female | 14 | 17 | 14 | 21 | 66 |
| Transgender | 0 | 0 | 2 | 0 | 2 |
| Unknown | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 38 | 43 | 40 | 44 | 165 |
| White | 3 | 3 | 0 | 2 | 8 |
| More than one race | 5 | 1 | 2 | 3 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| United States | 46 | 47 | 42 | 49 | 184 |
| Less than 12 years of education(Participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Count of participants | 9 | 14 | 13 | 23 | 59 |
| Employed(Participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Count of participants | 16 | 15 | 8 | 7 | 46 |
| Taking antiretroviral medication(Participants) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Count of participants | 42 | 47 | 41 | 47 | 177 |
| Cigarettes smoked per day(cigarettes per day) | Varenicline and Standard of Care | Placebo and Standard of Care | Positively Smoke Free and Placebo | Positively Smoke Free and Varenicline | Total |
|---|---|---|---|---|---|
| Mean | 11.7 ± 6.8 | 11.0 ± 5.3 | 11.6 ± 7.1 | 10.8 ± 5.7 | 11.3 ± 6.2 |
4 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome→
University of Maryland, Baltimore